Cargando…
Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide
Insulin sensitizers and incretin mimetics are antidiabetic agents with vastly different mechanisms of action. Thiazolidinedione (TZD) insulin sensitizers are associated with weight gain, whereas glucagon-like peptide-1 receptor agonists can induce weight loss. We hypothesized that combination of a T...
Autores principales: | Kamm, Dakota R., Pyles, Kelly D., Sharpe, Martin C., Healy, Laura N., Colca, Jerry R., McCommis, Kyle S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192871/ https://www.ncbi.nlm.nih.gov/pubmed/34022222 http://dx.doi.org/10.1016/j.jbc.2021.100807 |
Ejemplares similares
-
Treating fatty liver disease by modulating mitochondrial pyruvate metabolism
por: Colca, Jerry R., et al.
Publicado: (2017) -
An Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer’s Disease
por: Shah, Raj C, et al.
Publicado: (2014) -
Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer
por: Colca, J R, et al.
Publicado: (2013) -
Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches
por: Giannoukakis, Nick, et al.
Publicado: (2023) -
Enhancing Hepatic MBOAT7 Expression in Mice With Nonalcoholic Steatohepatitis
por: Sharpe, Martin C., et al.
Publicado: (2023)